Treatment and prophylaxis of venous thromboembolism during pregnancy

Thrombosis Research

Volumn 108, Issue 2-3, 2002, Pages 97-106

  Bates, Shannon M ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Heparin; Low molecular weight heparin; Pregnancy; Prophylaxis; Treatment; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; COUMARIN DERIVATIVE; DANAPAROID; HEPARIN; HEPARINOID; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; THROMBIN INHIBITOR; WARFARIN;

BLEEDING; DEEP VEIN THROMBOSIS; EMBRYOPATHY; HUMAN; LUNG EMBOLISM; OSTEOPOROSIS; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; PROBABILITY; REVIEW; RISK FACTOR; TERATOGENESIS; THROMBOEMBOLISM;

EID: 0036878876     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00399-7     Document Type: Review

References (111)

1. Sachs B.P., Brown D.A., Driscoll S.G., Schulman E., Acker D., Ransil B.J.et al. Maternal mortality in Massachusetts. Trends and prevention. N. Engl. J. Med. 316:1987;667-672.
2. Atrash H.K., Koonin L.M., Lawson H.W., Franks A.L., Smith J.C. Maternal morbidity in the United States 1979-1986. Obstet. Gynecol. 76:1990;1055-1060.
3. Hogberg U., Innala E., Sandstrom A. Maternal mortality in Sweden. Obstet. Gynecol. 84:1994;240-244.
4. Rutherford S.E., Phelan J.P. Thromboembolic disease in pregnancy. Clin. Perinatol. 13:1986;719-739.
5. Walker M.C., Garner P.R., Keely E.J. Thrombosis in pregnancy: a review. J. SOGC. 20:1998;943-952.
6. Anderson B.S., Steffensen F.H., Sorensen H.T., Nielson G.L., Olsen J. The cumulative incidence of venous thromboembolism during pregnancy and puerperium - an 11 year Danish population based study of 63,300 pregnancies. Acta Obstet. Gynecol. Scand. 77:1998;110-113.
7. Nordstom M., Lindblad B. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J. Intern. Med. 232:1992;155-160.
8. Aaro L.A., Juergens J.L. Thrombophlebitis associated with pregnancy. Am. J. Obstet. Gynecol. 109:1971;1128-1133.
9. Hiilsmaa V. Occurrence and anticoagulant treatment of thromboembolism in gravidas, parturients and gynecologic patients: a study of 678 cases treated in the Women's Clinic of the University of Helsinki in 1953-1957. Acta Obstet. Gynecol. Scand. 39:1960;5-12. [Suppl.].
10. Jeffcoaate T.N.A., Miller J., Roos R.F., Tindall V.R. Puerperal thromboembolism in relation to inhibition of lactation by estrogen therapy. Br. Med. J. 3:1968;19-25.
11. Tengborn L., Bergqvist D., Matzsch T., Bergqvist A., Hedner U. Recurrent thromboembolism in pregnancy and puerperium. Am. J. Obstet. Gynecol. 28:1985;107-118.
12. Ginsberg J.S., Brill-Edwards P., Burrows R.F., Bona R., Prandoni P., Buller H.R.et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb. Haemost. 67:1992;519-520.
13. Kent N., Leduc L., Crane J., Farine D., Hodges S., Reid G.J.et al. Prevention and treatment of venous thromboembolism (VTE) in obstetrics. J. SOGC. 95:2000;736-742.
14. Ikard R.W., Ueland K., Folse R. Lower limb venous dynamics in pregnant women. Surg. Gynecol. Obstet. 132:1971;483-488.
15. Macklon N.C., Greer I.A., Bowman A.W. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br. J. Obstet. Gynaecol. 104:1997;191-197.
16. Metcalfe J., Ueland K. Maternal cardiovascular adjustments to pregnancy. Prog. Cardiovasc. Dis. 16:1974;363-374.
17. Kerr M.G., Scott D.B., Samuel E. Studies of the inferior vena cava in late pregnancy. Br. Med. J. 1:1964;532-533.
18. Cockett F.B., Thomas M.L. The iliac compression syndrome. Br. J. Surg. 52:1965;816-821.
19. Hull R.D., Raskob G.E., Carter C.J. Serial impedance plethysmography in pregnant patients with clinically suspected deep vein thrombosis. Ann. Intern. Med. 112:1990;663-667.
20. Stirling Y., Woolf L., North W.R., Seghatchian M.J., Meade T.W. Haemostasis in normal pregnancy. Thromb. Haemost. 52:1984;176-182.
21. Woodhams B.J., Candotti G., Shaw R., Kernoff P.B. Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion. Thromb. Res. 55:1989;99-107.
22. Bonnar J. Blood coagulation and fibrinolysis in obstetrics. Clin. Hematol. 12:1973;58-63.
23. Comp P.C., Thurnau G.R., Welsh J., Esmon C.T. Functional and immunologic protein S levels are decreased during pregnancy. Blood. 68:1986;881-885.
24. Clark P., Brennand J., Conkie J.A., McCall F., Greer I.A., Walker I.D. Activated protein C sensitivity, protein C, protein S, and coagulation in normal pregnancy. Thromb. Haemost. 79:1998;1166-1170.
25. Wright J.G., Cooper P., Astedt B., Lecander I., Wilde J.T., Preston F.E.et al. Fibrinolysis during normal human pregnancy: complex interrelationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br. J. Haematol. 69:1988;253-258.
26. Bremme K., Ostlund E., Almqvist I., Heinonen K., Blomback M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet. Gynecol. 80:1992;132-137.
27. Kruithof E.K., Tran-Thang C., Gudinchet A., Hauert J., Nicoloso G., Genton C.et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood. 69:1987;460-466.
28. Lindqvist P.G., Svensson P.J., Marsaal K., Grenner L., Luterkort M., Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb. Haemost. 81:1999;532-537.
29. Gerhardt A., Scharf R.E., Beckmann M.W., Struve S., Bender H.G., Pillny M.et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N. Engl. J. Med. 342:2000;374-380.
30. Grandone E., Margaglione M., Colaizzo D., D'Andrea G., Cappucci G., Brancaccio V.et al. Genetic susceptibility to pregnancy-related venous thromboembolism. Roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am. J. Obstet. Gynecol. 179:1998;1324-1328.
31. Simioni P., Sanson B.J., Prandoni P., Tormene D., Friederick P.W., Girolami B.et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb. Haemost. 81:1999;198-202.
32. Martinelli I., Bucciarelli P., Margagline M., de Stafano V., Castaman G., Munnucci P.M. The risk of venous thromboembolism in family members tih mutations in the genes of factor V or prothrombin or both. Br. J. Haematol. 111:2000;1223-1229.
33. Martinelli I., Sacchi I., Landi G., Taioli E., Duca F., Mannucci P.M. High risk of cerebral vein thrombosis in carriers of a prothrombin gene mutation and in users of oral contraceptives. N. Engl. J. Med. 338:1998;1793-1797.
34. Conrad J., Horellou M.H., Van Dreden P., Lecompte T., Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women (letter). Thromb. Haemost. 63:1990;319-320.
35. Hellgren M., Tengborn L., Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol. Obstet. Investig. 14:1982;127-141.
36. De Stefano V., Leone G., Mastrangelo S., Tripodi A., Rodeghiero F., Castaman G.et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S (letter). Thromb. Haemost. 71:1994;799-800.
37. Friederich P.W., Sanson B.J., Simioni P., Zanardi S., Huisman M.V., Kindt I.et al. Frequency of pregnancy related venous thromboembolism in anticoagulant deficient women: implications for prophylaxis. Ann. Intern. Med. 125:1996;955-960.
38. Ginsberg J.S., Wells P.S., Brill-Edwards P., Donovan D., Moffatt K., Johnston M.et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 83:1995;3685-3691.
39. McColl M.D., Ramsay J.I., Tait R.D., Walker I.D., McCall F., Conkie J.A.et al. Risk factors for pregnancy associated venous thromboembolism. Thromb. Haemost. 78:1997;1183-1188.
40. Geerts W.H., Heit J.A., Clagett G.P., Pineo G.F., Colwell C.W., Anderson F.A. Jr.et al. Prevention of venous thromboembolism. Chest. 119:2001;132S-175S. [Supplement].
41. Hyers T.M., Agnelli G., Hull R.D., Morris T.A., Samama M., Tapson V.et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 119:2001;176S-193S. [Supplement].
42. Bauer K.A.et al. Fondaparinux compared with Enoxparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med. 345:2001;1305-1310.
43. Eriksson B.I.et al. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med. 345:2001;1298-1304.
44. Turpie A.G.G.et al. Postoperative Fondaparinux versus postoperative Enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 359:2002;1721-1726.
45. de Valk H.W., Banga J.D., Webster J.W.J., Brouwer C.B., van Hessen M.W., Meuwissen O.G.et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. Ann. Intern. Med. 123:1995;1-9.
46. Wo Y.L., Allard S., Cohen H., Letsky E., de Swiet M. Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia. BJOG. 109:2002;466-468.
47. Gill J., Kovacs M.J. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy. Obstet. Gynecol. 90:1997;648-650.
48. Taylor A.A. Successful use of heparinoids in a pregnancy complicated by allergy to heparin. BJOG. 108:2001;1011-1012.
49. Macchi L., Sarfati R., Guicheteau M., Chamlian V., Pourrat O., Gruel Y.et al. Thromboembolic prophylaxis with danaparoid (Orgaran) in a high-thrombosis-risk pregnant women with a history of HIT and Widal's disease. Clin. Appl. Thromb./Hemost. 6:2000;187-189.
50. Rey E., Rivard G.E. Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int. J. Gynaecol. Obstet. 71:2000;19-24.
51. Ginsberg J.S., Greer I., Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 119:2001;122S-131S. [Supplement].
52. Lagrang F., Vergnes C., Brun J.L., Paolucci F., Nadal T., Leng J.J.et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra). Thromb. Haemost. 87:2002;831-835.
53. Quick A.J. Experimentally induced changes in the prothrombin level of the blood: III. Prothrombin concentration of newborn pups of a mother given Dicoumarol before parturition. J. Biol. Chem. 164:1946;371-376.
54. Hall J.G., Pauli R.M., Wilson K.M. Maternal and fetal sequelae of anticoagulants during pregnancy. Am. J. Med. 68:1980;122-140.
55. Ginsberg J.S., Hirsh J., Turner C., Levine M.N., Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb. Haemost. 61:1989;197-203.
56. Chan W.S., Anand S., Ginsberg J.S. Anticoagulation of pregnant women with mechanical heart valves. A systematic review of the literature. Arch. Intern. Med. 160:2000;191-196.
57. Iturbe-Alessio I., del Carmen Fonesca M., Mutchinik O., Santos M.A., Zajarias A., Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N. Engl. J. Med. 315:1986;1390-1393.
58. Hirsh J., Cade J.F., Gallus A.S. Fetal effects of Coumadin administered during pregnancy. Blood. 36:1970;623-627.
59. Orme M.L., Lewis P.J., de Swiet M., Serlin M.J., Sibeon R., Baty J.D.et al. May mothers given warfarin breastfeed their infants? Br. Med. J. 1:1977;1564-1565.
60. McKenna R., Cole E.R., Vasan U. Is warfarin sodium contraindicated in the lactating mothers? J. Pediatr. 103:1983;325-327.
61. Flessa H.C., Kapstrom A.B., Glueck H.I., Will J. Placental transport of heparin. Am. J. Obstet. Gynecol. 93:1965;570-573.
62. Ginsberg J.S., Kowalchuk G., Hirsh J., Brill-Edwards P., Burrows R. Heparin therapy during pregnancy: risks to the fetus and mother. Arch. Intern. Med. 149:1989;2233-2236.
63. Hull R., Delmore T., Carter C., Hirsh J., Genton E., Gent M.et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N. Engl. J. Med. 306:1982;189-194.
64. Hull R., Hirsh J., Jay R., Carter C., England C., Gent M.et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N. Engl. J. Med. 307:1982;1676-1681.
65. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M.et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N. Engl. J. Med. 332:1995;1330-1335.
66. Griffith G.C., Nichols G., Asher J.D., Flahagan B. Heparin osteoporosis. J. Am. Med. Assoc. 193:1965;85-94.
67. Ginsberg J.S., Kowalchuk G., Hirsh J., Brill-Edwards P., Burrows R., Coates G.et al. Heparin effect on bone density. Thromb. Haemost. 64:1990;286-289.
68. Douketis J.D., Ginsberg J.S., Burrows R.F., Duku E.D., Webber C.C., Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density: a prospective matched cohort study. Thromb. Haemost. 75:1996;254-257.
69. Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am. J. Obstet. Gynecol. 168:1993;1265-1270.
70. Dahlman T.C., Lindvall N., Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study post-partum. Br. J. Obstet. Gynaecol. 97:1990;221-228.
71. Zimran A., Shilo S., Fisher D., Bab I. Histomorphic evaluation of reversible heparin-induced osteoporosis in pregnancy. Arch. Intern. Med. 146:1986;386-388.
72. Muir J.M., Hirsh J., Weitz J.I., Andrew M., Young E., Shaughnessy S.G. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood. 89:1997;3236-3242.
73. Bhandari M., Hirsh J., Weitz J.I., Young E., Venner T.J., Shaughnessy S.G. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb. Haemost. 80:1998;413-417.
74. Anderson D.R., Ginsberg J.S., Burrows R., Brill-Edwards P. Subcutaneous heparin therapy during pregnancy: a need for concern at the time of delivery. Thromb. Haemost. 65:1991;248-250.
75. Anderson D.R., Ginsberg J.S., Brill-Edwards P., Demers C., Burrows R.F., Hirsh J. The use of an indwelling Teflon catheter for subcutaneous heparin administration during pregnancy. A randomized crossover study. Arch. Intern. Med. 153:1993;841-844.
76. Hirsh J., Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Circulation. 93:1996;2212-2245.
77. Forestier F., Daffos F., Copella-Paulovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb. Res. 34:1984;557-560.
78. Dimitrakakis C., Papageorgiou P., Papageorgiou I., Antzaklis A., Sakarelou N., Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis. 30:2000;243-248.
79. Ensom M.J., Stephenson M.D. Low-molecular-weight heparins in pregnancy. Pharmacotherapy. 19:1999;1013-1025.
80. Melissari E., Parker C.J., Wilson N.V., Monte G., Kanthou C., Pemberton K.D.et al. Use of low molecular weight heparin in pregnancy. Thromb. Haemost. 68:1992;652-656.
81. Hull R.D., Raskob G.E., Pineo G.F., Green D., Trowbridge A.A., Elliott C.G.et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N. Engl. J. Med. 326:1992;975-982.
82. Weitz J.I. Low-molecular-weight heparins. N. Engl. J. Med. 337:1997;688-698.
83. Monreal M., Lafoz E., Olive A., del Rio L., Vedia C. Comparison of subcutaneous unfractionated heparin with low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb. Haemost. 71:1994;7-11.
84. Pettila V., Leinonen P., Markkola A., Hiilesmaa V., Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb. Haemost. 87:2002;182-186.
85. Sefras J., Farquharson R.G. Bone density studies in pregnant women receiving heparin. Eur. J. Obstet. Gynecol. Reprod. Biol. 65:1996;171-174.
86. Dolovich L.R., Ginsberg J.S., Douketis J.D., Holbrook A.M., Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch. Intern. Med. 160:2000;181-188.
87. Gould M.K., Dembitzer A.D., Doyle R.L., Hastie T.J., Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann. Intern. Med. 130:1999;800-809.
88. Nurmohamed M.T., Rosendaal F.R., Buller H.R., Dekker E., Hommes D.W., Vandenbroucke J.P.et al. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 340:1992;152-156.
89. Leizorovicz A., Haugh M.C., Chapuis F.R., Samama M.M., Boissel J.P. Low-molecular-weight heparins in the prevention of perioperative thrombosis. Br. Med. J. 305:1992;913-920.
90. Sanson B., Lensing A.W.A., Prins M.H., Ginsberg J.S., Barkagan Z.S., Lavenne-Pardonge E.et al. The use of low-molecular-weight heparin in pregnancy: a systematic review. Thromb. Haemost. 81:1999;668-672.
91. Villasanta U. Thromboembolic disease in pregnancy. Am. J. Obstet. Gynecol. 93:1965;142-160.
92. Hull R.D., Raskob G.E., Rosenbloom D., Panju A.A., Brill-Edwards P., Ginsberg J.S.et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N. Engl. J. Med. 332:1990;1260-1264.
93. Raschke R.A., Reilly B.M., Guidry J.R., Fontana J.R., Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care nomogram" Ann. Intern. Med. 119:1993;874-881.
94. Levine M.N., Hirsh J., Gent M., Turpie A.G., Cruikshank M., Weitz J.et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch. Intern. Med. 154:1994;49-56.
95. Blomback M., Bremme K., Hellgren M., Lindberg H. A pharmacokinetic study of dalteparin (Fragmin) in late pregnancy. Blood Coagul. Fibrinolysis. 9:1998;343-350.
96. Casele H.L., Laifer S.A., Woelkers D.A., Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am. J. Obstet. Gynecol. 181:1999;1113-1117.
97. Hirsh J., Warkentin T.E., Shaughnessy S.G., Anand S.S., Halperin J.L., Raschke R.et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 119:2001;64S-94S. [Supplement].
98. Kearon C., Hirsh J. Management of anticoagulation before and after elective surgery. N. Engl. J. Med. 336:1997;1506-1511.
99. Badaracco M.A., Vessey M. Recurrent venous thromboembolic disease and the use of oral contraceptives. Br. Med. J. 1:1974;215-217.
100. Tengborn L. Recurrent thromboembolism in pregnancy and the puerperium: is there a need for thromboprophylaxis? Am. J. Obstet. Gynecol. 160:1989;90-94.
101. Guidelines on the presentation, investigation, and management of thrombosis associated with pregnancy. J. Clin. Pathol. 46:1993;489-496.
102. Colvin B.T., Barrowcliff T.W. The British Society for Haematology guidelines on the use and monitoring of heparin 1992: second revision. J. Clin. Pathol. 45:1993;97-103.
103. de Swiet M., Floyd E., Letsky E. Low risk of recurrent thromboembolism in pregnancy (letter). Hosp. Med. 38:1987;264.
104. Howell R., Fidler J., Letsky E., de Swiet M. The risk of antenatal subcutaneous heparin prophylaxis: a controlled trial. Br. J. Obstet. Gynaecol. 90:1983;1124-1128.
105. Brill-Edwards P., Ginsberg J.S., Gent M., Hirsh J., Burrows R., Kearon C.et al. Recurrence of clot in this pregnancy study group. N. Engl. J. Med. 343:2000;1439-1444.
106. Hallak M., Senderowicz J., Cassel A., Shapira C., Aghai E., Auslender R.et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am. J. Obstet. Gynecol. 176:1997;889-993.
107. 506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br. J. Haematol. 92:1996;473-478.
108. Dizon-Townson D.S., Nelson L.M., Jang H., Varner M.W., Ward K. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am. J. Obstet. Gynecol. 176:1997;883-886.
109. Martinelli I., Legnani C., Bucciarelli P., Grandone E., De Stefano V., Mannucci P.M. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb. Haemost. 86:2001;800-803.
110. Middeldorp S., Libourel E.J., Hamulyak K., Van der Meer J., Buller H.R. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br. J. Haematol. 113:2001;553-555.
111. Demers C., Ginsberg J.S. Deep vein thrombosis and pulmonary embolism in pregnancy. Clin. Chest Med. 13:1992;645-656.